BRCA1 clinical trials
68 active trials name this biomarker in their eligibility criteria (recorded in the registry as “BRCA1 Gene”) . Describe your situation to see which ones look like a fit.
- Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
- Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Study of AZD0754 in Participants With Metastatic Prostate Cancer
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
- Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
- Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
- Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Combination Therapy in Cancers With Mutations in DNA Repair Genes
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
- Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- Clinical Trial of PM54 in Advanced Solid Tumors Patients.
- Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
- Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
- Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
- Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
- Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
- The Cancer of the Pancreas Screening-5 CAPS5)Study
- Identifying and Caring for Individuals With Inherited Cancer Syndrome
- A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
- Study of How People Make Decisions About Prostate Cancer Risk
- Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
- Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer
- Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
- Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
- Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
- Prostate Cancer Genetic Risk Evaluation and Screening Study
- Pilot Study of Pancreatic Cancer Screening
- Pancreatic Cancer Screening for At-risk Individuals
- Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
- Men at High Genetic Risk for Prostate Cancer
- A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
- Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Pancreatic Cancer Early Detection Consortium
- PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “BRCA1 Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.